Journal of Immunology Research / 2018 / Article / Tab 3

Research Article

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 3

Comparisons of characteristics between patients with clinical benefit (CR, PR, and SD) and patients without clinical benefit (PD).

VariableNPatients with clinical benefit
()
Patients without clinical benefit
()
value

Clinical data
 Breslow index, median (mm)102.443.990.134
 PS > 0102/61/41.000
 LDH > N103/62/41.0000
 AJCC stage IV105/61/40.191
 Metastatic disease diagnosis to TIL injection, median (years)102.94.60.669
 Ipilimumab before TILs102/62/41.000
 Ipilimumab after TILs102/61/41.000
 TILs infused, median (×109)108.15.50.609
BRAF mutation V600E92/52/41.000
 c-KIT mutated101/60/41.000
TIL phenotypes
 CD3+997.70%96.23%0.914
 CD3 + CD4+956.98%47.04%0.914
 CD3 + CD8+934.58%36.78%0.914
 CD4 + CD25+a98.50%5.56%1.000
 CD4 + CD25 + CD127lowCTLA4+916.89%19.07%0.3524
 CD4 + CD25 + CD127lowFoxp3+b930.71%20.49%0.1714

AJCC: American Joint Committee on Cancer; CI: confidence interval; LDH: lactate dehydrogenase; PS: performance status. aPercentage among the CD3+ population. bPercentage among the CD4 + CD25+ population.